Lausanne Metropolitan Area
Forward-looking leader with a proven track record in development of highly complex systems, including robotically assisted surgical devices and in leading digital transformation initiatives. Combines deep expertise in RD hardware and embedded software engineering with strong strategic acumen and a solid foundation in data and digital technologies. Recognized by executives, peers, and cross-functional teams as high-performing, collaborative, and mission-driven professional. Executive MBA in Healthcare Management at HEC Lausanne (’23). Led Distalmotion's R&D from 3 to 55 FTEs and guided the Dexter® surgical robot from concept to US commercial launch.
I serve as DigeHealth's fractional Strategic & Technology Advisor (~20%), supporting the team on technology strategy. DigeHealth develops wearable solutions that monitor gut health by measuring bowel sounds and vital body metrics 24/7.
Operator-led venture capital backing Swiss/DACH Deeptech scaleups with CHF 250k–1M tickets. We've scaled companies ourselves — we bring the scar tissue, not just the capital. The operator DNA your cap table has been missing.
- Serving as a member of the Solution Leadership team at Distalmotion, with responsibility for the company’s Digital Transformation initiatives, encompassing Business Transformation, Data and IT. - Successfully redefined strategy, organizational structure, processes and critical business systems (e.g. ERP, CRM) roadmap in the context of an IPO gap assessment.
- Scaled R&D teams from 3 to 55 FTEs, with hands-on leadership in talent acquisition, having conducted over 200 interviews. - Built and structured teams across hardware development, embedded software, application software, intellectual property, robotics, and mechanical engineering. Proactively planned and executed key hires in preparation for FDA De Novo submission. - Accountable for the end-to-end systems architecture of the Dexter® robotic platform—a robotic solution supporting laparoscopic surgery—delivered from concept to European CE mark certification under the Medical Device Directive (MDD), including First-in-Human clinical use. - Contributed significantly to the definition of the regulatory strategy for CE marking and U.S. FDA De Novo clearance, including the identification of key risk control measures in alignment with applicable standards, relevant laws and regulations, and current state-of-the-art practices - Contributed to early-stage financing rounds through technical due diligence and investor presentations, collaborating with leading private equity, strategic investors and private investors.
- Developed initial prototypes for Dexter (hardware, embedded software, robotics) together with a small team of talented engineers.
Thermo Fisher Scientific manufactures laboratory analyzers designed to perform rapid analysis of solid metallic samples, material characterization through destructive and non-destructive elemental analytical techniques. My role at Thermo Fisher Scientific was to manage a team of 3 FTE developers developing and maintaining manufacturing support software to the Optical Emission Spectrometry (OES) and X-Ray Fluorescence (XRF) product lines. I am also responsible for developing product lifecycle management initiatives within the R&D department, and to follow-up on Engineering Change Requests and Non-Conformities.
My role at Thermo Fisher Scientific was to model, design and implement embedded hardware and firmware on the Optical Emission Spectrometry product line and to support our application scientists to deliver the required analytical performances for our instruments.
Project manager on an innovative Medical Device, for stem cell cryopreservation with temperature control, mixing and liquid delivery systems.